Gastrointestinal Stromal Tumor in a Liver Transplant Recipient

Saidi, Reza F.; Sepehr, Alireza; Cosimi, A. Benedict; Hertl, M

doi:10.1097/tp.0b013e31816c7e2f

Cited by 9 publications

(8 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Saidi et al [9] reported a case of a GIST and Camargo et al [10] reported a case of an EGIST, both in liver transplant recipients; however, they did not perform genetic analysis. This is the first case of a posttransplant EGIST occurring in a renal transplant recipient with the tumor arising in the pelvic cavity which is an extraordinary unusual anatomical location.…”

Section: Discussionmentioning

confidence: 97%

Extragastrointestinal stromal tumor in a kidney transplant recipient

Cai

et al. 2011

Clin Exp Nephrol

View full text Add to dashboard Cite

The occurrence of de novo malignant neoplasms has been shown in post-transplant recipients receiving immunosuppressive treatment. We present a case of a rare extragastrointestinal stromal tumor (EGIST) located in the pelvic cavity of a kidney transplant patient. A 57-year-old female patient was admitted to our department because of non-specific lower abdominal pain 6 months after renal transplantation. An abdominal computed tomography scan showed a 4.5 cm diameter pelvic tumor mass. The tumor was resected en bloc and confirmed as not being connected to the gastrointestinal wall. Microscopically, the tumor consisted of typical spindle cells with 2-3 mitotic figures per 50 high-power fields. Immunohistochemically, the tumor cells were strongly positive for CD117 (c-kit), and negative for CD34, SMA, s-100 protein, and desmin. Genetically, the tumor showed a silent mutation in exon 18 of the PDGFRA gene at codon 824 GTC > GTT (V824V) [rs2228230]. No recurrence was noted 24 months after the operation. This case draws our attention to the importance of considering EGISTs (including GISTs), even though they are extremely uncommon, in the differential diagnosis of mesenchymal neoplasms, especially in transplant patients.

show abstract

Section: Discussionmentioning

confidence: 97%

Extragastrointestinal stromal tumor in a kidney transplant recipient

Cai

et al. 2011

Clin Exp Nephrol

View full text Add to dashboard Cite

show abstract

“…No risk factors or predisposing conditions have been identified 2 3. Gastrointestinal bleeding (50%) is the most common presentation, followed by abdominal pain (20–50%) 4. Approximately a third is detected incidentally 4.…”

Section: Discussionmentioning

confidence: 99%

“…Gastrointestinal bleeding (50%) is the most common presentation, followed by abdominal pain (20–50%) 4. Approximately a third is detected incidentally 4. Prognosis depends on the size of the tumour and number of mitoses per 50 high-power microscopic fields 2.…”

Section: Discussionmentioning

confidence: 99%

“…Saidi et al 4 presented a case of GIST in a recipient with liver transplantation who was on tacrolimus and AZA for immunosuppression. A 54-year-old man underwent a routine colonoscopy 11 months after transplant, which revealed a 2.5 cm tumour located at the hepatic flexure.…”

Section: Discussionmentioning

confidence: 99%

“…Despite this, GIST cases involving patients with transplantation have seldom been reported 3 4. In 2007, Agaimy et al 3 reported the first two cases of GIST in renal transplant recipients.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Gastrointestinal stromal tumour in a recipient with kidney transplantation

et al. 2015

View full text Add to dashboard Cite

Immunosuppression is associated with an increased risk of post-transplant malignancies. Gastrointestinal stromal tumours are the most common mesenchymal tumours of the gastrointestinal tract. However, they have seldom been reported recipient with transplantation. In this report, a 46-year-old woman, a recipient with kidney transplantation, who developed a gastric tumour is presented. Removal of this tumour required a partial gastrectomy. Histopathology and immunohistochemistry examinations revealed a high-risk gastric stromal tumour. Adjuvant imatinib mesylate treatment was initiated. There was no evidence of tumour recurrence at 12-month follow-up.

show abstract